Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Benefits of timely basal insulin control in patients with type 2 diabetes

February 8th 2015

Lovre D, Fonseca V. Journal of Diabetes and its Complications. Doi: 10.1016/j.jdiacomp.2014.11.018

Chronic hyperglycaemia is associated with the micro and macro vascular complications of diabetes. Legacy studies from both DCCT and UKPDS have demonstrated long term reductions in macro vascular complications following early glucose control, not shown when glucose is controlled late in the condition – a situation which may even be harmful. Despite all the attention paid to newer agents, insulin remains the most potent hypoglycaemia agent and is most likely to safely maintain HbA1c<7% as well as attaining normoglycaemia in some newly diagnosed patients. Although cost is an issue, basal insulin analogues are associated with lower hypoglycaemia and weight gain compared with NPH insulin. Furthermore, patients can be taught how to titrate insulin quite easily although their acceptance of early insulin use can be an obstacle as can health care professional training. Finally, when combined with a GLP1 analogue, hypoglycaemia and weight gain can be further reduced. In fact, the next few years will see a number of products combined in a single device.
http://www.jdcjournal.com/article/S1056-8727(14)00372-9/abstract

Categories: Journal Watch

Journal Watch Archive

calendar-iconJournal Watch Archive ››

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Napp DiabetesAstraZenecaSanofi DiabetesNovo Nordisk

Silver Sponsors

Welsh Endocrinology and Diabetes Society (WEDS)Abbott Diabetes CareAmgen

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership